5.74
+0.07(+1.23%)
Currency In USD
| Previous Close | 5.67 |
| Open | 5.69 |
| Day High | 5.87 |
| Day Low | 5.5 |
| 52-Week High | 7.73 |
| 52-Week Low | 1.34 |
| Volume | 341,895 |
| Average Volume | 921,657 |
| Market Cap | 192.71M |
| PE | -7.45 |
| EPS | -0.77 |
| Moving Average 50 Days | 4.3 |
| Moving Average 200 Days | 2.7 |
| Change | 0.07 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $1,564.03 as of December 25, 2025 at a share price of $5.74. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $2,870 as of December 25, 2025 at a share price of $5.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 09, 2025 10:45 PM GMT
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refract
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 07, 2025 11:20 PM GMT
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 1
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
GlobeNewswire Inc.
Dec 07, 2025 11:15 PM GMT
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasin